SOURCE: CAPITAL NEWS CIRCUIT

August 03, 2012 07:30 ET

Immunovative, Inc. Appoints Former University of Colorado Cancer Center Research Manager to Director of Regulatory Affairs

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the CAPITAL NEWS CIRCUIT

NEW YORK, NY--(Marketwire - Aug 3, 2012) - The following is an investment opinion on Immunovative, Inc (OTCBB: IMUN), Dendreon (NASDAQ: DNDN), Galena Biopharma (NASDAQ: GALE) and Johnson & Johnson (NYSE: JNJ). Immunovative, Inc. (OTCBB: IMUN) has announced the appointment of former University of Colorado Cancer Center manager of clinical research, Dr. Zivile Katiliene. Dr. Katiliene will provide the company with oversight of the company's clinical research programs, including budgeting for resources, communicating with the project teams, and establishing performance metrics to measure the impact of clinical operations.

In an article from Seeking Alpha on the recent downfall of Dendreon Corp (NASDAQ: DNDN) and the 2012 upswing of Galena Biopharma (NASDAQ: GALE) it is mentioned briefly that companies like Johnson & Johnson (NYSE: JNJ) are also in the immunotherapy arena, like Immunovative, with drugs aimed at using the body's own immune system to help fight cancer. The recent additions of Dr. Katiliene and Bruno Vanderschelden could help Immunovative reach the milestones they have outlined in their ImmuNews newsletter and stay competitive with the other companies in the immunotherapy arena.

To read more on Immunovative, please visit www.imuninfo.com

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information